Status:
COMPLETED
24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
Lead Sponsor:
Aristotle University Of Thessaloniki
Conditions:
Glaucoma
Eligibility:
All Genders
29-80 years
Phase:
PHASE4
Brief Summary
The proposed study will compare for the first time the quality of 24-hour IOP control with Brimonidine/Timolol fixed combination (BTFC) versus Dorzolamide/Timolol fixed combination (DTFC) after a run-...
Eligibility Criteria
Inclusion
- Consecutive, newly diagnosed or previously untreated POAG patients
- Patients with typical glaucomatous disc, or visual field damage
- Patient must have IOP (at 10:00 ± 1 hour)greater than 25 mm Hg
Exclusion
- Uncontrolled glaucoma
- Distance best corrected Snellen visual acuity worse than 1/10
- Contraindications to brimonidine or dorzolamide and β-blockers
- History of lack of response (\<10% morning IOP reduction) to any medication
- Patient can not understand the instructions and adhere to medications
- Patient is a female of childbearing potential or lactating mother
- Prior surgery, past use of steroids (within 2 months)
- Severe dry eyes and use of contact lenses
- History of non-adherence
- Patients with closed angles
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00972257
Start Date
January 1 2009
End Date
September 1 2009
Last Update
May 12 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glaucoma Unit, 1st University Dept of Ophthalmology
Thessaloniki, Greece, 546 36